CD274 and neoplasm: Moreover, the combination of lenvatinib—a multi-tyrosine kinase (TK) inhibitor—with anti-PD-1/PD-L1 mAb reduced tumor volume and improved survival in immunocompetent mice with orthotopic ATC [229].